Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 355-361 , October 2003

The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors

  • Marzena Welnicka-Jaskiewicz

      Affiliations

    • Corresponding Author InformationCorrespondence to: Dr. Marzena Welnicka-Jaskiewicz, Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki Street, Gdansk 80-211, Poland. Tel.: +48-58-349-2270; Fax: +48-58-520-3899
    • ,
  • Jacek Jassem

References 

  1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047–1059
  2. Van Leeuwen FE, Rookus MA. The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer. Eur. J. Cancer Clin. Oncol. 1989;25:1961–1972
  3. Manson JE, Martin KA. Postmenopausal hormone-replacement therapy. N. Engl. J. Med. 2001;345(1):754–761
  4. Santen R, Pike M, Manson J, Ross R. Recent studies bring risks, benefits of hormone replacement therapy under security. J. Natl. Cancer Inst. 2001;93(17):1287–1288
  5. Hulley S, Furberg C, Cauley J, et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and oestrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:58–65
  6. Loprinzi CL, Quella SK, Sloan JA, et al.  Preliminary data from a randomized evaluation of fluoxetine (Prozac) for treating hot flashes in breast cancer survivors. Breast Cancer Res. Treat. 1999;57:34
  7. Grodstein P, Chen J, Pollen DA, et al.  Postmenopausal hormone therapy and cognitive function in healthy older women. J. Am. Geriatr. Soc. 2000;48:746–752
  8. Mulnard RA, Cotman CW, Kawas C, et al.  Oestrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial: Alzheimer’s Disease Cooperative Study. JAMA. 2000;283:1007–1015
  9. Barrett-Connor E. Hormone replacement therapy. Br. J. Cancer. 1998;317:457–461
  10. Willhite LA, O’Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy. 2001;21:464–480
  11. Samsioe G. Medical and surgical strategies for treating urogynecological disorders. Int. J. Fertil. Menopausal Stud. 1996;41:136–141
  12. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999;353:571–580
  13. Barret-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Annu. Rev. Public Health. 1998;19:55–72
  14. Grodstein P, Manson JE, Colditz G, et al.  A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 2000;133:933–941
  15. Hulley S, Grady D, Bush T, et al.  Randomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  16. Effects of oestrogen or oestrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Oestrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208
  17. Grady D, Herrington D, Bittner V, et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and oestrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:49–57
  18. Hemmiki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. Br. Med. J. 1997;315:149–153
  19. Lenfant C. Preliminary trends in the Women’s Health Initiative. Bethesda, MD: National Heart, Lung and Blood Institute Communications Office; 2000;
  20. Grady D, Gebretsadik T, Kerlikowske K, et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 1995;85:304–313
  21. Skoog I, Gustafson D. HRT and dementia. J. Epidemiol. Biostat. 1999;4:227–251
  22. Ursin G, Tseng Ch, Paganini-Hill A, et al.  Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?. J. Clin. Oncol. 2002;20:699–706
  23. Matthews K, Cauley J, Yaffe K, et al.  Oestrogen replacement therapy and cognitive decline in older community women. J. Am. Geriatr. Soc. 2000;48:345–346
  24. Hulka BS. Effect of exogenous oestrogen on postmenopausal women: the epidemiologic evidence. Obstet. Gynecol. 1980;35:398–399
  25. Wingo PA, Layne PM, Lee NC, et al.  The risk of breast cancer in postmenopausal women who have used oestrogen replacement therapy. JAMA. 1987;257:209–215
  26. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int. J. Cancer. 1988;42:832–838
  27. Toniolo PG, Levitz M, Zelenich-Jacquotte , et al.  A prospective study of endogenous oestrogens and breast cancer in postmenopausal women. J. Natl. Cancer Inst. 1995;87:190–197
  28. Persson I, Weiderpass E, Bergkvist L, et al.  Risk of breast and endometrial cancer after oestrogen and progestin replacement. Cancer Causes Control. 1999;10:253–260
  29. Schairer C, Lubin J, Troisi R, et al.  Menopausal oestrogen and oestrogen/progestin replacement therapy and breast cancer risk. JAMA. 2000;283:485–491
  30. Olsson HL, Bladstrom A, Ingvar C. Hormone replacement therapy containing progestins and given continuously especially increases breast cancer risk in southern Sweden. Breast Cancer Res. Treat. 2002;76:S37
  31. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J. Clin. Oncol. 1998;16:3115–3120
  32. Willis DB, Calle EE, Miracle-McMahill H, et al.  Oestrogen replacement therapy and risk of fatal breast cancer in prospective cohort of postmenopausal women in the United States. Cancer Causes Control. 1991;7:449–457
  33. Grodstein F, Stampfer M, Colditz C, et al.  Postmenopausal hormone therapy and mortality. N. Engl. J. Med. 1997;336:1769–1775
  34. Schairer C, Gail M, Byrne C, et al.  Oestrogen replacement therapy and breast cancer survival in a large screening study. J. Natl. Cancer Inst. 1999;91:264–270
  35. Bergkvist L, Adami HO, Persson I. Prognosis after breast cancer diagnosis in women exposed to oestrogen and oestrogen/progestogen replacement therapy. Am. J. Epidemiol. 1989;130:221–228
  36. Magnusson C, Holmberg L, Norden T, et al.  Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res. Treat. 1996;38:325–334
  37. Ross RK, Paganini-Hill A, Wan PC, et al.  Effect of hormone replacement therapy on breast cancer risk: oestrogen vs. oestrogen plus progestin. J. Natl. Cancer Inst. 2000;92:328–332
  38. Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of oestrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
  39. Clamp A, Danson S, Clemons M. Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet. 2002;3:611–619
  40. Dupont WD, Page DL, Parl FF, et al.  Oestrogen replacement therapy in women with a history of proliferative breast disease. Cancer. 1999;85:1277–1283
  41. Byrne C, Schairer C, Wolfe J, et al.  Mammographic features and breast cancer risk: effects with time, age and menopausal status. J. Natl. Cancer Inst. 1995;87:1622–1629
  42. Ursin G, Pike MC, Spice DW, et al.  Can mammographic densities predict effects of tamoxifen on the breast?. J. Natl. Cancer Inst. 1996;88:128–129
  43. Persson I, Thurfjell E, Holmberg L. Effect of oestrogen and oestrogen–progestin replacement regimens on mammographic breast parenchymal density. J. Clin. Oncol. 1997;15:3201–3207
  44. Greendale GA, Reboussin BA, Sie A, et al.  Effect of oestrogen and oestrogen–progestin on mammographic breast parenchymal density. Ann. Intern. Med. 1999;130:262–269
  45. Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and accuracy of mammographic screening. Lancet. 2000;355:270–274
  46. Hortobagyi GN, Buzdar AU, Marcus CE. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Hospital and Tumor Institute. National Cancer Institute Monograph No. 1, National Cancer Institute: 1986; 105–110
  47. Samaan NA, DeAsis DN, Buzdar AU, et al.  Pituitary ovarian function in breast cancer patients on adjuvant chemo-immunotherapy. Cancer. 1978;41:2084–2087
  48. Vassilopoulou-Sellin R, Zolinski C. Oestrogen replacement therapy in women with breast cancer. A survey of patients attitudes. Am. J. Med. Sci. 1992;304:145–149
  49. Eden JA, Bush T, Nand S, et al.  A case-control study of combined continuous oestrogen–progestin replacement therapy among women with a personal history of breast cancer. Menopause. 1995;2:67–72
  50. Mortimer JE, Boucher L, Baty J, et al.  Effect of tamoxifen on sexual functioning in patients with breast cancer. J. Clin. Oncol. 1999;17:1488–1492
  51. Marsden J. Hormone-replacement therapy and breast cancer. Lancet. 2002;3:303–311
  52. Chang J, Powles T, Ashley SE, et al.  The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomized trial, controlled tamoxifen prevention study. Ann. Oncol. 1996;7:671–675
  53. Fisher B, Costantino JP, Wickerham DL, et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 1998;90:1371–1387
  54. Cummings SR, Eckert S, Krueger KA, et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA. 1999;23:2189–2197
  55. IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 2002; 360: 817–824
  56. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Oestrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol. Oncol. 1996;65:89–93
  57. Vassilopoulou-Sellin R, Asmar L, Hortobagyi N, et al.  Oestrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J. Clin. Oncol. 1999;17:1482–1487
  58. Cobleigh MA, Berris RF, Bush T, et al.  Oestrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA. 1994;272:540–545
  59. Colditz GA. Oestrogen replacement therapy for breast cancer patients. Oncology (Huntingt). 1997;11:1491–1497
  60. O’Meara ES, Rossing MA, Daling JR, et al.  Hormone replacement therapy after diagnosis of breast cancer in relation to recurrence and mortality. J. Natl. Cancer Inst. 2001;93:754–761
  61. Holmberg L. HABITS, Hormonal replacement therapy after breast cancer diagnosis—is it safe? Protocol for randomized clinical study concerning hormonal replacement therapy after previous radical breast cancer treatment, 1997
  62. Loprinzi CL, Barton DL, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet. 1997;350:1047–1059
  63. Loprinzi CL, Kugler JW, Maillard JA, et al.  Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet. 2000;356:2059–2063
  64. Loprinzi CL, Quella SK, Sloan JA, et al.  Preliminary data from a randomized evaluation of fluoxetine (Prozac) for treating hot flashes in breast cancer survivors. Breast Cancer Treat. 1999;57:34
  65. Delmas PD, Bjarnason NH, Mitlak BH, et al.  Effect of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997;337:1641–1647
  66. Clemons M, Clamp A, Anderson B. Management of the menopause in cancer survivors. Cancer Treat. Rev. 2002;28:321–333

PII: S0305-7372(03)00067-7

doi: 10.1016/S0305-7372(03)00067-7

Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 355-361 , October 2003

Article Tools